Lantheus Holdings Net Interest Income Over Time
| LNTH Stock | USD 90.96 0.44 0.49% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Lantheus Holdings Performance and Lantheus Holdings Correlation. Lantheus |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantheus Holdings. If investors know Lantheus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantheus Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.05) | Earnings Share 6.02 | Revenue Per Share 21.687 | Quarterly Revenue Growth 0.184 | Return On Assets 0.17 |
The market value of Lantheus Holdings is measured differently than its book value, which is the value of Lantheus that is recorded on the company's balance sheet. Investors also form their own opinion of Lantheus Holdings' value that differs from its market value or its book value, called intrinsic value, which is Lantheus Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantheus Holdings' market value can be influenced by many factors that don't directly affect Lantheus Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantheus Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantheus Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantheus Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Interest Income Analysis
Compare Lantheus Holdings and related stocks such as Neurocrine Biosciences, Deciphera Pharmaceuticals, and Ironwood Pharmaceuticals Net Interest Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NBIX | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | (19.5 M) | (30.5 M) | (32 M) | (32.8 M) | (25.8 M) | (7.1 M) | (4.6 M) | (4.8 M) |
| IRWD | (38 M) | (38 M) | (38 M) | (38 M) | (38 M) | (38 M) | (38 M) | (34.3 M) | (34.7 M) | (33.7 M) | (28 M) | (30.4 M) | 1.9 M | 8.5 M | 8.9 M |
| ALKS | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (7.4 M) | (6.2 M) | 375 K | (1.7 M) | (8.8 M) | (5.4 M) | 7.8 M | 8.2 M |
| AVDL | (963 K) | (963 K) | (963 K) | (963 K) | (963 K) | (963 K) | (963 K) | (1.1 M) | (10.6 M) | (12.5 M) | (13 M) | (9.9 M) | (12.3 M) | (9.9 M) | (10.4 M) |
| ANIP | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (11.3 M) | (12 M) | (14.8 M) | (13 M) | (9.5 M) | (11.9 M) | (28.1 M) | (28.7 M) | (27.3 M) |
| RDY | (76 M) | (76 M) | (76 M) | (76 M) | (76 M) | (76 M) | (76 M) | (248 M) | (119 M) | (90 M) | 1.7 B | 2.1 B | (1.4 B) | 567 M | 327 M |
| COLL | (94 K) | (94 K) | (94 K) | (94 K) | (94 K) | (94 K) | (94 K) | 582 K | (18.4 M) | 1 M | (28.6 M) | (21 M) | (62.2 M) | (67.7 M) | (64.3 M) |
| PCRX | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (5.7 M) | (14 M) | (15.5 M) | (16.3 M) | (21 M) | (30.9 M) | (35.4 M) | (17.2 M) | (18 M) |
| ALVOW | (96.8 M) | (96.8 M) | (96.8 M) | (96.8 M) | (96.8 M) | (96.8 M) | (96.8 M) | (96.8 M) | (96.8 M) | (96.8 M) | (100.5 M) | (114.5 M) | (90.5 M) | (130 M) | (136.5 M) |
| CTLT | (88.5 M) | (88.5 M) | (88.5 M) | (88.5 M) | (88.5 M) | (88.5 M) | (90.1 M) | (123.2 M) | (126.7 M) | (126.1 M) | (110 M) | (127 M) | (184 M) | (254 M) | (241.3 M) |
| AMPH | (754 K) | (754 K) | (754 K) | (754 K) | (754 K) | (754 K) | (754 K) | (401 K) | 213 K | 878 K | 268 K | (284 K) | (525 K) | (14.5 M) | (13.8 M) |
| DERM | (255 K) | (255 K) | (255 K) | (255 K) | (255 K) | (255 K) | (255 K) | (255 K) | (255 K) | (255 K) | (698 K) | (7 M) | (2 M) | (2 M) | (2.1 M) |
| AQST | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (7.7 M) | (7.2 M) | (8.7 M) | (12.9 M) | (22 M) | (12.3 M) | 8.9 M | 9.3 M |
| DVAX | 755 K | 755 K | 755 K | 755 K | 755 K | 755 K | 755 K | 1.3 M | (5.5 M) | (13.6 M) | (17.8 M) | (11 M) | 1.2 M | 20 M | 21 M |
Lantheus Holdings and related stocks such as Neurocrine Biosciences, Deciphera Pharmaceuticals, and Ironwood Pharmaceuticals Net Interest Income description
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.My Equities
My Current Equities and Potential Positions
| Lantheus Holdings | LNTH |
| Classification | Trump Equities |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 90.96
Check out Lantheus Holdings Performance and Lantheus Holdings Correlation. For more detail on how to invest in Lantheus Stock please use our How to Invest in Lantheus Holdings guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Lantheus Holdings technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.